Teva buys 51% equity share of Immuneering Corp.

JERUSALEM and CAMBRIDGE, Mass. — Teva Pharmaceutical Industries Ltd. on Monday announced that it will buy a 51% equity share of Immuneering Corp., a genomic-analysis company.

Privately held Immuneering uses “advanced proprietary techniques” to research genetic, genomic and proteomic data, Teva said.

"Immuneering brings together state-of-the-art analytics know-how with expertise in integrating multiple biologically and clinically relevant inputs," Michael Hayden, president of Teva Global R&D and chief scientific officer, said. "Their ability to cut through, link and interpret enormous and disparate data-sets is outstanding.”

Through the partnership between Teva’s team and the MIT-trained Immuneering team, the companies “will be closer to helping match the right patient to the right medicine at the right time," he added.

Teva and Immuneering previously collaborated on research relating to genetic biomarkers, therapy-specific gene expression signatures and characterizing non-biological complex drugs, according to the company.

Teva now holds the right of first refusal in projects relating to developing treatment for central nervous system disorders, the company said.

“Immuneering is pioneering new ways to use gene expression and genomic data to elucidate the biological mechanisms underlying both the development of disease, and the effectiveness of medicines,” Ben Zeskind, CEO and co-founder of Immuneering, said. “Combining Immuneering's technology platform and expertise with Teva's world-class scientific knowledge, intensity and devotion to patient benefit is a logical next step to build on the success of the Teva/Immuneering collaborations to date.”